Stifel Remains Bullish on Tango Therapeutics (TNGX)

For further context, Tango Therapeutics, Inc. (NASDAQ:TNGX) reported successful its fiscal Q4 and afloat twelvemonth 2025 results that it held $343.1 cardinal successful cash, currency equivalents, and marketable securities, which it expects to money operations into 2028. It further reported that collaboration gross for the 4th was $0 compared to $5.4 cardinal for the aforesaid play successful 2024, and $62.4 cardinal for the afloat year, compared to $30.0 cardinal for the anterior twelvemonth period.

It added that each of the remaining deferred gross nether the Gilead collaboration was recognized arsenic collaboration gross during fiscal Q3 2025 arsenic a effect of the truncation of the collaboration agreement, which concluded each probe activities.

Tango Therapeutics, Inc. (NASDAQ:TNGX) is simply a clinical-stage biotechnology institution that discovers and delivers precision crab medicines. The institution is besides progressive successful the recognition of caller targets and the improvement of caller drugs directed astatine tumor suppressor cistron nonaccomplishment successful defined diligent populations with precocious unmet aesculapian need.

While we admit the imaginable of TNGX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey connected Google News.